header logo image


Page 349«..1020..348349350351..360370..»

The art of the segue – Lone Peak Lookout

October 29th, 2020 11:00 pm

It was negative three degrees outside when Evi Dixon remarked on what a beautiful day it was. Originally from Austria, she is no stranger to a white world and chilly temperatures. Actually, snow is what initially brought her to Big Sky the plan was to work one season abroad as a ski instructor. Instead of returning immediately, she met a fella and had two children. They all moved back to Austria, but her ex husband missed home and returned to Montana.

She described Big Sky as a tiny, deserted little place in the early days, particularly in the summer and fall no one was around. Twelve years later, Dixon returned to a different Big Sky, a thriving mountain, and she would meet a new man. For years, she worked on the mountain in the ski school office, at BASE Camp when it was just starting, she became an EMT, a ski patroller and eventually an accident investigation supervisor for ski patrol, where she would take pictures and measurements, find witnesses and record the data. Dixon also did avalanche patrol, became a dispatcher and eventually trained dispatchers, a job she describes as one people rarely want, but that is important.

She believes she was the oldest woman to ever start professionally patrolling at Big Sky Resort.

A rough divorce in 2015 led her to another path, but first through a gauntlet of pain.

I gave myself up completely to [my marriage], she said softly with her slight accent. I was at the bottom of my energy. I had to do something. I couldnt wait any longer because I was really thinking of ending my life. I needed to do something so I started my own business.

From there, she said she found meaning and not just from a feeling of purpose, but also from positive interactions with new people, working on her personal development, her mindset.

It gave me so much hope. I really love it. Theres always a reason or a silver lining behind what happens, she said. Im here. Im happy. It still hurts what happened. That was really awful. I try to look to my future and get my feet on the ground. In Austria, she was a therapist. So after her divorce, she returned to her roots. Helping people makes her happy.

In Austria, she studied kinesiology and became a craniosacral therapist. Her focus is in frequency medicine. What some people may define as Eastern Medicine she refers to as integrative. She believes the eastern and western ways of medicine can work together and create the best possible outcomes for patients.

Her home business now involves the Healy, a device created by a German physicist and engineer who was a monk in India for 20 years. He created a handheld device that has similar capabilities as a large machine. With a team of doctors behind it, Dixon explained that it has applications for things like pain management, sleep, concentration, meridians, chakras, the whole gamut.

I can scan peoples biodynamics and their electric fields. It tells me what frequency people need and then it sends out the frequencies through the electromagnetic or biodynamic field, since we are all energy, we are all biodynamic, we are all frequency, every piece of music, every tree we are all connected, she said. She can treat people in Australia or India and has even treated animals.

Whatever Dixon decides to pursue she does with determination and a willingness to learn. A few years ago, she wanted to find animals to keep the grass mowed down on her property. After settling on alpacas and launching her business Spanish Peaks Alpacas, she learned to shear them and now travels around to other farms to help with shearing. From there, she learned how to spin yarn, how to knit and weave.

In many ways, she is the consummate entrepreneur, allowing for one pursuit to lead her to another and into a further understanding of entire industries. She continues to diversify her portfolio.

Dixon even recently became an author of an ebook titled, Activate Your Inner Healer, that contains 10 tips for self healing.

Life has never really been easy on her, she said. Her challenges started when she lost her parents as a little girl.

We are all going through trauma, but I still believe that Im a lucky person, she said.

When difficulties stack and she begins feeling overwhelmed, she does what she can to get herself recentered.

Meditate, go out and hug a tree, go listen to inspirational videos, go and dance. Or if its time to cry, its time to cry, she said. The main thing is that we have stories that happen and we have to understand the things that happen they are not happening to us, they are happening for us. That is a little bit of difference in the wording, but it is a big difference in the meaning. Life goes on and we have to deal with it. We are just going to become stronger.

More:
The art of the segue - Lone Peak Lookout

Read More...

Comprehensive Report on Nutrigenomics Market by global COVID-19 impact analysis, industry trends, business strategies, opportunities and forecast to…

October 29th, 2020 11:00 pm

Report Ocean recently published Nutrigenomics Market report which highlights the important factors that are expected to shape the growth of the Nutrigenomics Market over the forecast period. The current trends, market drivers, opportunities, and restraints are thoroughly evaluated to provide a clear understanding of the current market landscape of the Nutrigenomics Market. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Nutrigenomics Market.

The COVID-19 (Coronavirus) outbreak has led to both advantages and disadvantages for companies in the Nutrigenomics Market. With the help of our recently published report, market players can adopt innovative strategies to overcome the challenges that lie ahead of the COVID-19 lockdown period. Through our research study, companies can gain factual information about COVID-19 and how its impacting the sales of products in the global market landscape.

Request Free Sample Report athttps://reportocean.com/industry-verticals/sample-request?report_id=mai66474

The report covers exhaustive analysis on:

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain in the Nutrigenomics Market. The report Nutrigenomics Market provide in-depth analysis of current market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on Nutrigenomics Market segments and geographies.

This Nutrigenomics Market report begins with a basic overview of the market. The analysis highlights the opportunity and Nutrigenomics Market trends that are impacted the market. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Nutrigenomics Market insight regarding the things which are driving and affecting the earnings of the market.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:

Market Data Breakdown by Key Geography, Type & Application / End-User

By type (past and forecast)

Nutrigenomics Market: Specific Applications Sales and Growth Rates (Historical & Forecast)

Nutrigenomics Market revenue and growth rate by the market (history and forecast)

Nutrigenomics Market size and growth rate, application and type (past and forecast)

Competitive Landscape:Key players in the global Nutrigenomics market covered in Chapter 4:DSM N.V.XCODE Life Sciences Pvt. Ltd.Nutrigenomics New ZealandBASF SENutrigenomixMetagenics, IncDNALIFEGenomix Nutrition, Inc.Cura Integrative MedicineNutraGeneWellGen Inc.DanoneGX Sciences

Nutrigenomics Market competitive landscape provides details and data information by Major Players. Details included are company description, major business, company total revenue and the sales, revenue generated in Nutrigenomics Market business, the date to enter into the Nutrigenomics Market, product introduction, recent developments, etc.

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of Nutrigenomics Market.

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India, Middle East and Africa and Central and South America.

Study objectives of Nutrigenomics Market Report:

To provide economic factors, technology trends, and market trends that influence the global Nutrigenomics Market growth

To provide historical, current, and forecast revenue of market segments and sub-segments with respect to regional markets and key countries

To provide historical, current, and forecast revenue of market segments based on material, type, design, and end-user

To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the global Nutrigenomics Market

To provide strategic profiling of key players in the market, comprehensively analyzing their market shares, core competencies, and drawing a competitive landscape for the market

Inquire or Share Your Questions If Any before Purchasing This Report:https://reportocean.com/industry-verticals/sample-request?report_id=mai66474

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

The rest is here:
Comprehensive Report on Nutrigenomics Market by global COVID-19 impact analysis, industry trends, business strategies, opportunities and forecast to...

Read More...

Cardiac Autonomic Neuropathy Treatment Market Is Pegged To Reach A Value Of US$ XX Mn/Bn By The End Of 2017 2025 – Aerospace Journal

October 29th, 2020 10:59 pm

In this report, the global Cardiac Autonomic Neuropathy Treatment market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Cardiac Autonomic Neuropathy Treatment market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Cardiac Autonomic Neuropathy Treatment market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14518

The major players profiled in this Cardiac Autonomic Neuropathy Treatment market report include:

key players in Cardiac autonomic neuropathy treatment market are Pfizer Inc., Roche Holding AG, Novartis, Amgen Inc., Privi Pharma Limited, Silverline Chemicals Limited, Anthem Biopharma, Praxis Pharmaceutical.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

The regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14518

The study objectives of Cardiac Autonomic Neuropathy Treatment Market Report are:

To analyze and research the Cardiac Autonomic Neuropathy Treatment market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Cardiac Autonomic Neuropathy Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Cardiac Autonomic Neuropathy Treatment market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14518

Visit link:
Cardiac Autonomic Neuropathy Treatment Market Is Pegged To Reach A Value Of US$ XX Mn/Bn By The End Of 2017 2025 - Aerospace Journal

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market and Forecast 2020-2026 – KYT24

October 29th, 2020 10:59 pm

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Chemotherapy Induced Peripheral Neuropathy Treatment market.

Trusted Business Insights presents an updated and Latest Study on Chemotherapy Induced Peripheral Neuropathy Treatment Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Chemotherapy Induced Peripheral Neuropathy Treatment market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Chemotherapy Induced Peripheral Neuropathy Treatment Market and Forecast 2020-2026

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

By region, the United States has the highest share of income, reaching 47.25 percent in 2019.

Market Analysis and Insights: Global Chemotherapy Induced Peripheral Neuropathy Treatment MarketThe research report studies the Chemotherapy Induced Peripheral Neuropathy Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.

The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is projected to reach US$ 2276.6 million by 2026, from US$ 1572.6 million in 2020, at a CAGR of 6.4% during 2021-2026.Global Chemotherapy Induced Peripheral Neuropathy Treatment Scope and Segment

The global Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by

Application for the period 2015-2026.

by Type, the market is primarily split into

by Application, this report covers the following segments

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

The Chemotherapy Induced Peripheral Neuropathy Treatment key players in this market include:

Looking for more? Check out our repository for all available reports on Chemotherapy Induced Peripheral Neuropathy Treatment in related sectors.

Quick Read Table of Contents of this Report @ Global Chemotherapy Induced Peripheral Neuropathy Treatment Market and Forecast 2020-2026

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

More:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market and Forecast 2020-2026 - KYT24

Read More...

Global Neuropathy Pain Treatment Market 2020 Comprehensive Analysis, Future Estimations, Growth Drivers and Forecast to 2027 – re:Jerusalem

October 29th, 2020 10:59 pm

The Neuropathy Pain Treatment Market Report begins with an overview of the industrial chain structure and provides an overview of the industrial environment, analysis of market size, by-products, regions, application forecasts, and market competition with vendors and companies. Introduction to the situation This report describes the profile, as well as the analysis of market prices and the characteristics of the value chain.

This report provides informed decisions, opportunity understanding, effective business strategy planning, new project planning, peer and constraint analysis, and industry forecast projection. Neuropathy Pain Treatment Market Report Includes Breakdown of Top Players, Dealer Strategies, Dealer Analysis, Marketing Channels, Potential Buyers, and Market Development.

Apply FREE Sample Report (Get Full Insights in PDF) with Tables, Charts, and Graphs:https://www.worldwidemarketreports.com/sample/350599

This study provides a detailed analysis of the market in terms of regulatory framework and development trends, historical data, market size, and future prospects. The report provides a detailed analysis of market segments and sub-segments investigating market trends and demand in key regions of the global Neuropathy Pain Treatment market. Joint ventures also refer to various elements such as mergers, partnerships, and product launches.

Global Neuropathy Pain Treatment Market Segmentation as Follows:

By Top Industry Players:, Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals,

By Type:, Calcium channel alpha 2-delta ligands, Serotonin-norepinephrine reuptake inhibitors, Others,

By Application:, Retail Pharmacies, Hospitals, Others,

This research report provides an analysis of the competitive landscape of the global Neuropathy Pain Treatment market. This includes evaluating current and future trends that players can invest in. It also includes an assessment of the players financial prospects and describes the nature of the competition.

The report now describes the changes in market dynamics and demand patterns associated with COVID-19 infection. This report provides a detailed overview of business areas, growth prospects, and future prospects based on the impact of COVID-19 on the growth of the entire industry. The report also provides an analysis of the current and future market impact of Pandemic and a forecast of COVID-19 anomalies.

Get the Free Analysis with this Report (Covers Updated Covid-19 Impact Analysis on Neuropathy Pain Treatment Industry):https://www.worldwidemarketreports.com/covidimpact/350599

The main questions answered in the report are:

The research report describes the potential development opportunities that exist in the global market. The reports are classified by research methods based on historical information and forecasts. The global market for Neuropathy Pain Treatment is generous and dependent on the size and assets of the incentive measurement period. This report provides an understanding of the evolution of openness and control in market making. The search can generate significant awareness of the final destination of the market.

Production Analysis- Production is analyzed for different regions, types and uses. It also provides price analysis to various market participants.

Sales and Revenue Analysis- Examine both sales and revenue in different regions of the global market. Another important aspect that plays an important role in earnings and prices is also evaluated in different regions of this section.

Supply and consumption- This section analyzes the supply and consumption of the market that continues to sell. This part also shows the gap between supply and consumption. Import and export numbers are also listed here.

Other Analytics- Provides market information, sales analysis, and contact information for top manufacturers, suppliers, and top consumers. This includes SWOT analysis of new projects and suitability analysis of new investments.

This data stream also includes sales prices for different types, applications, and regions. An important regional market is offered. It also includes consumption by type and by applicable star.

Do you have any questions? Contact our industry expert:https://www.worldwidemarketreports.com/quiry/350599

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email:sales@worldwidemarketreports.com

Read more:
Global Neuropathy Pain Treatment Market 2020 Comprehensive Analysis, Future Estimations, Growth Drivers and Forecast to 2027 - re:Jerusalem

Read More...

Vitamin D3 metabolite ratio as an indicator of vitamin D status and its association with diabetes complications – DocWire News

October 29th, 2020 10:58 pm

This article was originally published here

BMC Endocr Disord. 2020 Oct 27;20(1):161. doi: 10.1186/s12902-020-00641-1.

ABSTRACT

BACKGROUND: Vitamin D deficiency is diagnosed by total serum 25-hydroxyvitamin D (25(OH)D) concentration and is associated with poor health and increased mortality; however, some populations have low 25(OH) D concentrations without manifestations of vitamin D deficiency. The Vitamin D Metabolite Ratio (VMR) has been suggested as a superior indicator of vitamin D status. Therefore, VMR was determined in a population with type 2 diabetes at high risk for vitamin D deficiency and correlated with diabetic complications.

RESEARCH DESIGN AND METHODS: Four hundred sisty patients with type 2 diabetes (T2D) were recruited, all were vitamin D3 supplement naive. Plasma concentration of 25-hydroxyvitamin D3 (25(OH)D3) and its metabolites 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) and its epimer, 3-epi-25-hydroxyvitamin D3 (3-epi-25(OH)D3), were measured by LC-MS/MS analysis. VMR-1 was calculated as a ratio of 24,25(OH)2D3:25(OH)D3; VMR-2 as a ratio of 1,25(OH)2D3:25(OH)D3; VMR-3 was calculated as a ratio of 3-epi-25(OH)D3: 25(OH)D3. RESULTS: An association means that there were significant differences between the ratios found for those with versus those without the various diabetic complications studied. VMR-1 was associated with diabetic retinopathy (p = 0.001) and peripheral artery disease (p = 0.012); VMR-2 associated with hypertension (p < 0.001), dyslipidemia (p < 0.001), diabetic retinopathy (p < 0.001), diabetic neuropathy (p < 0.001), coronary artery disease (p = 0.001) and stroke (p < 0.05). VMR-3 associated with hypertension (p < 0.05), dyslipidemia (p < 0.001) and coronary artery disease (p < 0.05).

CONCLUSIONS: In this cross sectional study, whilst not causal, VMR-2 was shown to be the superior predictor of diabetic and cardiovascular complications though not demonstrative of causality in this cross-sectional study population over VMR-1, VMR-3 and the individual vitamin D concentration measurements; VMR-2 associated with both microvascular and cardiovascular indices and therefore may have utility in predicting the development of diabetic complications.

PMID:33109163 | DOI:10.1186/s12902-020-00641-1

Read more:
Vitamin D3 metabolite ratio as an indicator of vitamin D status and its association with diabetes complications - DocWire News

Read More...

OmniTier Streamlines Personalized Medicine Workflows with CompStor Insight for Next-Generation Sequencing Tertiary Analysis – BioSpace

October 29th, 2020 10:57 pm

Oct. 27, 2020 12:00 UTC

The only tertiary analysis appliance on the market, CompStor Insight delivers 7x faster annotation in an easy to use solution with integrated workflows, multi-user support, needing no special IT skills

MILPITAS, Calif.--(BUSINESS WIRE)-- OmniTier Inc., an AI and multiomics application company whose bioinformatics solutions help deliver the promise of personalized medicine, debuted the CompStor Insight appliance for tertiary analysis in next-generation sequencing (NGS) applications. In benchmark results, CompStor Insight enables a 7x improvement in gene annotation performance allowing researchers to spend more time developing treatment innovations, and less time on data processing.

OmniTier made the announcement coincident with the ASHG 2020 virtual meeting, where it will showcase CompStor Insight and other members of the CompStor genomics analysis product family.

Our researchers are very busy because we need to analyze and interpret complex variants of many patients, said Kazuhiro Nitta, lecturer at Juntendo Universitys Graduate School of Medicine in Tokyo, and part of the Intractable Disease Research Center. He collaborated with OmniTier on CompStor Insight product development. It was an enjoyable experience to work with the innovative team at OmniTier. With the level of automation and sophisticated filtering that is supported by CompStor Insight, we estimate we could reduce the amount of time for downstream analysis of multi-genomic data sets dramatically.

Personalized medicine initiatives have put the spotlight on tertiary analysis as the most complex step in NGS, where scientists seeking better treatments for cancer or rare diseases investigate variants identified during secondary analysis. Competing open source solutions and internally developed applications in use today for tertiary analysis often exhibit low level of functional automation and require long data ingress-compute-egress cycles delay time to actionable data that does not scale with more server nodes.

CompStor Insight is the first tertiary analysis appliance on the market and enables faster time to results, and low per-subject cost. With an easy set up and straightforward Web browser interface, it provides push-button workflows for annotation, filtering, visualization and querying variant data. Utilizing OmniTiers proprietary MemStac tiered memory technology, CompStor Insight can process up to several thousand genome datasets at speed, enabling faster and more accurate interpretation of data in genome-wide-association studies (GWAS) and rare disease analysis. Because CompStor Insight is designed to interface to a wide range of standard and custom knowledge databases including ClinVar and gnomAD, teams have access to a wide set of reference data at their fingertips. Being a stand-alone appliance, CompStor Insight can store subject data locally in on-premise storage, or leverage cloud storage options.

In testing, CompStor Insight delivered a 7x reduction in run time to annotate typical WGS data, compared to Ensembl VEP. For NGS service businesses, where time is money, CompStor accelerates the annotation and filtering functions dramatically, providing an opportunity to grow their revenue and profit easily.

When used with OmniTiers secondary analysis appliance, CompStor Novos, organizations benefit from an end-to-end analytics solution, from sequencer output, advanced variant calling, and fast annotation, to state-of-the-art multisubject tertiary analysis. Pharmaceutical and biotech companies can take advantage of CompStor Insights intuitive GWAS workflows to identify biomarkers for drug development and develop subject selection strategies.

As the cost of gene sequencing decreases, many organizations are looking for faster, easier ways to learn from each patients data, and convert data to knowledge, said Christi Bird, principal consultant and fellow in Frost & Sullivan's Transformational Health Growth consulting team. OmniTier is addressing a key growth market as the bioinformatics industry works to enable the mass adoption of genomic medicine.

Researchers are straining to meet the explosive demand for personalized medicine with analytics that burden them with complexity and delays that impede the ability to turn data into knowledge and then treatments, said Hemant Thapar, CEO and founder of OmniTier. CompStor Insight is enabling the low per subject cost and faster turnaround time to actionable data that is critical to delivering better treatments for hundreds of diseases and genetic conditions.

CompStor Insight appliances will start shipping to pharmaceutical and research organizations in December 2020. For more information or to request pricing please visit http://www.omnitier.com.

About OmniTier Inc.

OmniTier develops AI and multiomics appliances and software for bioinformatics, scientific computing, and web services applications that deliver affordable real-time solutions to enrich everyday living. Its integrated appliance solutions accelerate data-intensive infrastructure applications, including genomic workflows and scientific analysis for machine learning and AI. Founded in February 2015, the company has R&D operations in Milpitas, CA and Rochester, MN.

CompStor Insight is for research purposes only. CompStor, CompStor Insight and MemStac are trademarks of OmniTier, Inc. CompStor Novos is a registered trademark of OmniTier, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005319/en/

See original here:
OmniTier Streamlines Personalized Medicine Workflows with CompStor Insight for Next-Generation Sequencing Tertiary Analysis - BioSpace

Read More...

Global Population Sequencing Market Report 2020: Market is Projected to Reach $64.04 Billion by 2030 from $21.73 Billion in 2020 – PRNewswire

October 29th, 2020 10:57 pm

DUBLIN, Oct. 28, 2020 /PRNewswire/ -- The "Global Population Sequencing Market: Focus on Product, Method, Technology, Application, Country, and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Growth in this market is expected to be driven by the rising adoption of large-scale sequencing to understand the genomics of susceptibility and resistance from COVID-19, increasing adoption of personalized medicine for the screening and diagnosis of genetic disorders, and a global surge in direct-to-consumer genetic testing.

However, there are significant challenges that are restraining the market growth, such as lack of infrastructure to maintain, store, and share sensitive genomic data, absence of sufficient funding for the development of high-throughput genomic software tools, and poor reducibility and transability of data in clinical practice.

The market is favored by the technological advancements in the sequencing, and computational analysis solutions for a large volume of genetic data enabling a deep understanding of the genetic variants for the development of diagnostics, drug discovery, and translational research.

Furthermore, several sequencing companies are focusing on the development of high-throughput sequence platforms and polymerase chain reaction platforms, with higher sensitivity and low turn-around time to benefit the patients, enabling patient-based outcomes and implementing genomic medicine.

Within the research report, the market is segmented on the basis of product type, application, methods, and technology. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of rapid diagnostics providing information on genetic mutation and optimal candidates for adjuvant chemotherapy or hormonal therapy. Due to the diverse product portfolio and intense market penetration, Illumina, Inc. has been a pioneer in this field and has been a significant competitor in this market.

The population sequencing market provided immense growth opportunities for the companies providing technology and infrastructure for large-scale health initiatives, such as Color Genomics, Inc., Helix Opco, LLC, and big data companies such as Genuity Science.

Key Questions Answered in this Report:

Key Topics Covered:

Executive Summary

1 Product Definition1.1 Definition by Product1.1.1 Platforms1.1.2 Kits and Assays1.1.3 Software Tools1.2 Inclusion and Exclusion1.2.1 Inclusion and Exclusion for Country-Wise Market Estimation1.3 Scope of Work1.4 Key Questions Answered in the Report

2 Research Methodology

3 Introduction3.1 Market Overview3.2 Impact of COVID-19 on Population Sequencing3.3 Future Potential

4 Global Population Sequencing Market Dynamics4.1 Overview4.2 Impact Analysis4.3 Market Drivers4.3.1 Rising Adoption of Large-Scale Sequencing to Understand the Genomics of Susceptibility and Resistance from COVID-194.3.2 Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders4.3.3 Global Surge in Direct-to-Consumer (DTC) Genetic Testing4.4 Market Restraints4.4.1 Lack of Infrastructure to Maintain, Store and Share Sensitive Genomic Data4.4.2 Absence of Sufficient Funding for Development of High-Throughput Genomic Software Tools4.4.3 Poor Reducibility and Translatability of Data in Clinical Practice4.5 Market Opportunity4.5.1 Advancing Precision Medicine with Blockchain-Powered Artificial Intelligence4.5.2 Technological Advancements in Sample Preparation for Population Sequencing4.5.3 Increased Population Engagement and Data Management

5 Competitive Landscape5.1 Key Strategies and Developments5.1.1 Product Approval5.1.2 Product Launches and Upgradations5.1.3 Synergistic Activities5.1.4 Funding and Expansion5.1.5 Acquisitions5.1.6 Other

6 Industry Insights6.1 Overview6.2 Legal Requirements and Framework in the U.S.6.3 Legal Requirements and Framework in Europe6.4 Legal Requirements and Framework in Asia-Pacific6.4.1 Japan6.5 Market Share Analysis (by Company) 20196.5.1 Growth Share Analysis (Opportunity Mapping)6.5.2 By Company

7 Global Population Sequencing Initiatives (by Country)

8 Global Population Sequencing Market (by Product), $Million, 2019-20308.1 Introduction8.2 Kits and Assays8.3 Platforms8.4 Software Tools

9 Global Population Sequencing Market (by Methods), $Million, 2019-20309.1 Introduction9.2 Whole Genome Sequencing9.3 Whole Exome Sequencing9.4 Single-Read Sequencing9.5 Other Sequencing Methods

10 Global Population Sequencing Market (by Technology), $Million, 2019-203010.1 Introduction10.2 Polymerase Chain Reaction (PCR)10.3 Next Generation Sequencing (NGS)10.4 Other Technologies

11 Global Population Sequencing Market (by Application), $Million, 2019-203011.1 Introduction11.2 Human health11.2.1 Clinical Applications11.2.1.1 Diagnostics11.2.1.1.1 Cancer Diagnostics11.2.1.1.2 Infectious Disease Diagnostics11.2.1.1.3 Rare Disease Diagnostics11.2.1.1.4 Other Diagnostics11.2.1.2 Drug Discovery and Development11.2.2 Translational Research Sequencing11.3 Molecular Forensics11.4 Blockchain in Genomics11.4.1 Data Sharing and Monetization11.4.2 Data Storage and Security11.4.3 Automated Health Insurance

12 Global Population Sequencing Market (by Country), $Million, 2019-2030

13 Company Profiles13.1 Company Overview13.2 Role of Agilent Technologies, Inc. in Global Population Sequencing Market13.3 Financials13.4 Key Insights About Financial Health of the Company13.5 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/aqpxxy

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Continue reading here:
Global Population Sequencing Market Report 2020: Market is Projected to Reach $64.04 Billion by 2030 from $21.73 Billion in 2020 - PRNewswire

Read More...

DCISionRT by PreludeDx Identifies Breast Cancer Patients Who May Be Undertreated with Surgery Alone – PRNewswire

October 29th, 2020 10:57 pm

LAGUNA HILLS, Calif., Oct. 29, 2020 /PRNewswire/ --Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented pivotal data at the American Society of Radiation Oncology (ASTRO) 2020 National Meeting on the company's present commercially available test, DCISionRT; as well as its new genomic signature presently in development for women with invasive breast cancer (IBC).

ASTRO Poster #2034, entitled Age and Grade as a Function of Decision Score in Women Diagnosed with DCIS, included nearly 1,800 women diagnosed with ductal carcinoma in situ (DCIS) and classified as clinicopathologically low-risk by RTOG-like criteria for recurrence of DCIS or progression to IBC.The DCISionRT assay reclassified almost half of these patients to elevated risk, suggesting a group of patients who would be under treated with surgery alone.

Furthermore, the data suggest both patient age and tumor grade failed to sufficiently risk stratify patients.DCISionRT Decision Score (DS) for women under 50 years of age classified 48% of the women to be very low and 52% to be very high biological risk of DCIS recurrence or progression to IBC over 10 years. This differs from the common expectation that the majority of women under 50 are at high risk and should therefore all undergo radiation post-surgery.

Additionally, almost half (48%) of women with low to intermediate tumor grade were reclassified as elevated risk by DCISionRT for DCIS recurrence or progression to IBC, thereby making tumor grade also inadequate as an independent risk indicator.

ASTRO Poster #2041, entitled A Novel Biosignature to Assess Residual Risk in Early Stage Invasive Breast Cancer after Standard Breast Conserving Surgery, provides new data to the company's biosignature that identifies which women diagnosed with stage 1 or 2 invasive breast cancer are most likely to have excellent versus poor outcomes after breast conserving surgery and radiation.

"It is heartening to see such robust data in support of DCISionRT testing to help physicians make treatment decisions for DCIS patients based on their own unique tumor biology instead of relying primarily on clinical features such as age and tumor grade," says Frank A. Vicini, MD, FACR, FASTRO, radiation oncologist at 21st Century Oncology."Additionally, I am excited about the promising data from the new biosignature for invasive breast cancer patients and look forward to the additional clinical benefits this will provide."

"We continue to remain laser focused on helping patients with early stage breast cancer determine the optimal treatment based on each woman's unique biology of her cancer tumor," says Dan Forche, President and CEO of PreludeDx."Today, we help patients and their physicians make the most personalized treatment decision at time of DCIS diagnosis with our commercially available DCISionRT product, and in the future, we look forward to helping patients diagnosed with invasive breast cancer do the same with products in our development pipeline."

About DCISionRT for Breast DCIS

DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. In the US, over 60,000 women are newly diagnosed with DCIS each year. The test was developed by PreludeDx and built on research that began with funding from the National Cancer Institute to better understand the biology of DCIS. DCISionRT assesses a woman's individual tumor biology along with other risk factors to provide a personalized recurrence risk. The test provides a Decision Scorethat identifies a woman's risk as low or elevated. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: http://www.preludedx.com

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.

CONTACT: Cory Dunn 888-211-DCIS(3247) [emailprotected]

SOURCE PreludeDx

https://preludedx.com

See the rest here:
DCISionRT by PreludeDx Identifies Breast Cancer Patients Who May Be Undertreated with Surgery Alone - PRNewswire

Read More...

Microsoft Cloud for Healthcare: Unlocking the power of health data for better care – Microsoft

October 29th, 2020 10:57 pm

As healthcare providers have faced unprecedented workloads (individually and institutionally) around the world, the pandemic response continues to cause seismic shifts in how, where, and when care is provided. Longer-term, it has revealed the need for fundamental shifts across the care continuum. As a physician, I have seen first-hand the challenges of not having the right data, at the right time, in the right format to make informed shared decisions with my patients. These challenges amplify the urgency for trusted partners and solutions to help solve emergent health challenges.

Today were taking a big step forward to address these challenges with the general availability of Microsoft Cloud for Healthcare. Microsoft Cloud for Healthcare brings together trusted capabilities to customers and partners that enhance patient engagement, empower health team collaboration, and improve clinical and operational insights. It makes it faster and easier to provide more efficient care and helps to ensure the end-to-end security, compliance, and interoperability of health data.

That starts with Azure API for FHIR, which enables the rapid exchange of data through Fast Healthcare Interoperability Resources (FHIR) APIs, backed by a managed platform as a service (PaaS) offering. It makes it easier for anyone working with health data to ingest, manage, and persist protected health information in the cloud. The healthcare industry is rapidly transforming health data to the emerging standard of FHIR, which enables a robust, extensible data model with standardized semantics and data exchange that enables all systems using FHIR to work together. Transforming your data to FHIR allows you to quickly connect existing data sources such as the electronic health record systems or research databases. FHIR also enables the rapid exchange of data in modern implementations of mobile and web development. Most importantly, FHIR can simplify data ingestion and accelerate development with analytics and Machine Learning tools. The shift from on-premises computing to the cloud in healthcare is one of the five megatrends I spoke about recently and is a one-time event happening in a more compressed period than other industries.

Another key innovation for Microsoft Cloud for Healthcare was born out of a Microsoft Hackathon and launched in 2019, but gained worldwide utilization this year during the pandemic. The Microsoft Health Bot service is an Azure cloud service that empowers healthcare organizations to rapidly build and deploy AI-powered virtual health assistants and chatbots that can be used to enhance their processes, self-service, and cost reduction efforts. The Health Bot comes with built-in healthcare AI services, such as clinical protocols and medical content from trusted industry sources, healthcare templates for rapid design, language understanding models that are tuned to understand medical and clinical terminology, and seamless hand-off to live chat and telehealth when required. The uptake of the Health Bot service has been incredible. Since March 2020, Microsofts Health Bot has triaged over 600 million messages and deployed 2,300 COVID-19 bots in 25 countries, to serve more than 50 million users. At a time when call centers and emergency departments were overwhelmed, this bot service has helped many hospital systems, non-government organizations (NGOs), and public health systems, including the US Center for Disease Control, to communicate up-to-date guidance, prioritize care for their most urgent patients, and receive real-time data on peoples interactions with the bot.

As we continue to expand the capabilities in Microsoft Cloud for Healthcare, our teams continue to bring forward innovations. Remote patient monitoring provides the ability to gather patient health data outside of traditional healthcare settings. Healthcare institutions can use Azure IoT Connector for FHIR to bring health data generated by remote devices into Azure API for FHIR. This data could be used to closely track patient health status, monitor patient adherence to treatment plans, and provide personalized care.

Recently released in Open Source, the Medical Imaging Server for DICOM streamlines the process of ingesting medical imaging data in the cloud. By using the Medical Imaging Server for DICOM alongside the Azure API for FHIR or other FHIR services, data references are created between imaging data and clinical data in FHIR, setting the stage for multiple scenarios which are difficult and expensive to execute in todays on-premises systems. As a radiologist, I am excited to see the development of Microsofts imaging server. Imaging data makes up 74 percentof all medical data and on our quest for patient-centered care, this imaging data often provides the clues to connect the dots in disease detection as well as to guide the most effective prevention and treatment strategies.

Text Analytics for Health, a feature of Microsoft Azure Text Analytics, is an AI service currently in preview that enables and simplifies the process of extracting insights from unstructured medical data. Trained on a diverse range of medical datacovering various formats of clinical notes, clinical trial protocols, and morethis health feature is capable of processing a broad range of data types and tasks, without the need for time-intensive, manual development of custom models. Much of todays healthcare data is in the form of unstructured text, such as doctors notes, medical publications, electronic health records, clinical trial protocols, medical encounter transcripts, and more. Healthcare organizations, providers, researchers, pharmaceutical companies, and others face an incredible challenge in trying to identify and draw insights from all that information. Unlocking insights from this data has massive potential for improving healthcare services and patient outcomes.

Future enhancements of Microsoft Cloud for Healthcare will include solutions for precision medicine. Decoding the information in an individuals genome has led to a greater understanding of the variability in disease progression and treatment response across individuals.Gaining a better understanding of these genetic variations at an individual and population level is key to development of precision medicine strategies to prevent, diagnose, and treat disease.Microsoft Genomicsopen source solutions (Cromwell on Azure, Genomics Notebooks) enable biomedical researchers to orchestrate scalable workflows and efficiently manage genomics pipelines and analytics using the power of the Azure cloud. Our goal is to make genomics data actionable by analyzing and interpreting data generated by modern genomics technologies.

Unlocking the power of health data with Microsoft Cloud for Healthcare and its expanding pipeline of enhancements allow care givers to gain a holistic view of the patient with insights and actionable next steps for more informed, personalized care management.

With todays launch, Microsoft Cloud for Healthcare lays the foundation for our customers and partners to build innovative solutions, leading to better experiences and outcomes for both patients and their providers. Collaborating with our partners to bring these innovations to life is the work that keeps me energized as we reimagine the future of health globally.

Read more:
Microsoft Cloud for Healthcare: Unlocking the power of health data for better care - Microsoft

Read More...

The good news about breast cancer – The Gazette

October 29th, 2020 10:57 pm

By Maggie Ireland, for The Gazette

October as Breast Cancer Awareness Month shines a spotlight on the battle against breast cancer and the developments in diagnosing and treating the disease that inspire hope for the future.

Breast cancer remains very common. Its still the most common cancer in women, said Dr. Ingrid Lizarraga, a clinical associate professor of surgery and breast surgeon at the University of Iowa Hospitals and Clinics in Iowa City.

But it is no longer the most common cause of death for women it is now the second most common cause of cancer death for women after lung cancer. We know a lot

more about breast cancer than we ever did before. The vast majority of women who have breast cancer will do great.

Admittedly, a breast cancer prognosis largely depends on the type of breast cancer you have and the stage at which it is diagnosed. The good news is that the prognosis has improved considerably over the years.

Mortality rates are decreasing, thanks to improved screenings and improved treatment, said Dr. Rasa Buntinas, an oncologist at PCI in Cedar Rapids. At our cancer center, 80 percent of women are diagnosed at an early stage stage 0 or stage 1 and that means a better chance of survival.

More screening options have become available in recent years.

Mammograms are still what we recommend, Lizarraga said. 3-D mammograms have been around for about five years and can be really helpful for women with dense

ARTICLE CONTINUES BELOW ADVERTISEMENT

breasts. The recognition that breast density affects how you screen is important. Whole breast ultrasounds can also be useful.

For women with abnormal findings, a breast MRI is an option.

Discussing your personal risk factors with your doctor is the best way to determine what screenings are best for you.

The latest developments in genetic testing can further pinpoint specific risk factors.

Weve identified a set of genes that puts you at high risk for developing breast cancer, and we can test for this gene, Lizarraga said. The trick is to find those at risk who need the genetic testing. If you have concerns, talk to your doctor so they can assess your risk and give you better guidance on a screening regimen.

Today, the widely accepted recommendation is for most women to begin getting an annual mammogram at age 40.

If you have any risk factors at all, start at 40. But the latest you should start is at age 45. And you should screen every year, Lizarraga said. When youre younger, the odds are lower, but the stakes are higher.

In the past, all women were encouraged to do a monthly self-exam, but thats no longer the case.

Self-exams are no longer recommended, Buntinas said. They tended to lead to more testing and biopsies but really didnt improve outcomes. The recommendation now

is breast self-awareness. Be aware of how your breasts look and feel, and report changes to your doctor.

Lizarraga agrees that a woman should trust her instincts if she senses something is wrong.

You know your body better than anyone else, she said. It doesnt just have to be a lump it could be a different appearance of the skin or the nipple. Pay attention to how you feel and how you look, and advocate for yourself if you notice something.

Many developments have been made in treating breast cancer, particularly metastatic breast cancer, Buntinas said.

Were really getting a much better understanding of tumor biology, she said. Specific targets are being identified to better improve treatments and provide more of a personalized medicine approach. In practice, these treatments are really improving survival.

Its an exciting time in the treatment of breast cancer, Lizarraga said, because things pretty much change every day.

If a woman needs a mastectomy, we can give you a result that looks much closer to what your native breast looks like, she said. The attitude used to be that you shouldnt worry about how it looks, because you should be grateful you dont have cancer, but thats not accepted anymore.

Advancements also are being made in addressing the side effects of treatment, like lymphedema, the swelling of a womans arm or hand that can follow the removal of lymph nodes.

Weve gotten better at figuring out more effective techniques that result in less lymphedema, Lizarraga said. Were also now better able to save a womans breasts if she prefers to do that.

The biggest advances in treatment, however, have been in systemic therapies, or the use of drugs to reach cancer cells anywhere in the body, she said.

Almost all women with breast cancer will get some form of systemic treatment pills or therapy.

ARTICLE CONTINUES BELOW ADVERTISEMENT

Weve become increasingly targeted with treatment, Lizarraga said. We start by figuring out which type of breast cancer you have. We now have genomic tests, so we can test the DNA of the tumor itself to see how likely it is to recur. That actually allows us to figure out whether a woman will benefit from chemotherapy or not.

Thats huge because we can limit the toxic treatment when its not going to be beneficial.

Treatment is more targeted than ever.

We match severity of treatment to the severity of disease, Lizarraga said. Weve figured out how to make things more personal in a lot of cases, weve changed the timing of treatment. In the past, you often came in, had surgery and then began the next form of treatment, like chemotherapy or pills.

Now, we often provide treatment before surgery and then personalize what is needed next.

Lizarraga said women of all ages need to know breast cancer is common but treatable, as long as its caught early.

If you do have a family history, be sure to get evaluated to see if genetic testing is appropriate, she said.

And know that who treats you is important, too.

Get a second opinion make sure the person youre seeing is someone who knows specifically about breast cancer treatment and the latest developments. Advocate for

yourself.

Both doctors agree the prognosis for breast cancer patients is brighter than ever.

The outlook is very positive and hopeful for the future, Buntinas said.

View original post here:
The good news about breast cancer - The Gazette

Read More...

Oxford BioDynamics Advances EpiSwitch Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University…

October 29th, 2020 10:57 pm

Oct. 28, 2020 11:00 UTC

OXFORD, England--(BUSINESS WIRE)-- Oxford Biodynamics Plc (AIM: OBD), a biotechnology company developing personalized medicine tests based on 3D genomic biomarkers, has signed a Human Material and Data Transfer Agreement with Oregon Health & Science University (OHSU) as part of its EpiSwitch COVID-19 disease severity test program.

Some people infected with COVID-19 become severely ill and hospitalized, while many only experience mild illness. Under the terms of the agreement, samples from OHSU will be used to further the development of the Companys COVID-19 severity test, aimed at forecasting individuals risks of severe disease progression in advance, to inform risk mitigation decisions and help optimize acute and long-term treatment.

Ranked among the best hospitals in the US,1 OHSU has been operating right at the frontline throughout the pandemic. Since 28 February, with the first US COVID-19 hotspot on its doorstep, OHSU has seen 3,950 patient cases, as of 26 October.2 Clinicians have encountered and treated patients experiencing a wide range of responses, from asymptomatic through to severe cases who were admitted to intensive care or succumbed.

OHSU is the first US Academic Medical Centre to join Oxford BioDynamics disease severity program on a non-commercial basis as part of the COVID-19 Technology Access Framework initiative it is involved with.3 OHSU is providing clinical research samples from patients with the full spectrum of manifestations of COVID-19, together with in-depth expert description and annotation. These add to Oxford BioDynamics growing bank of 500+ samples from cohorts across the world. The Company is developing the worlds first 3D genomic test to determine likelihood of disease severity (prognostic).

Dr Jon Burrows, CEO of Oxford BioDynamics commented: We are gratified that our disease severity program has attracted the attention and support of a prestigious institution like OHSU. The well-annotated samples provided by this world-class facility will deepen our understanding of patient response and enhance development of our test. We are continuing to grow our network of leading international institutions interested in analysing how the 3D genome informs COVID-19 response.

Oxford BioDynamics is developing the disease severity test based on its proprietary EpiSwitch technology which has been reduced to practice.4 EpiSwitch will be used to retrospectively analyse the OHSU samples, comparing the 3D genomes of the patients to how they responded to the virus. The 3D structure of a patients genome contains important molecular regulatory information, about what makes certain patients particularly vulnerable to hyperinflammation and severe side effects, when exposed to COVID-19 infection. Oxford BioDynamics is establishing a panel of biomarkers to forecast the expected severity when infected with COVID-19. This will help to assess an individuals level of risk and assist in patient prognoses. Having this information could significantly help patient triage and treatment, ease the burden on healthcare systems and human resources.

Bill Messer, MD, PhD, Assistant Professor of Molecular Microbiology and Immunology, School of Medicine, OHSU added: With the second wave of COVID-19 sweeping the globe, it is clear that we have a way to go in the fight against this virus. In April, we joined the COVID-19 Technology Access Framework, which aims to expedite the development of promising technologies to diagnose, treat and prevent COVID-19. Oxford BioDynamics shares the same mission, and their technology and its prognostic capabilities hold potential in helping both patients and the health care system. We are glad to contribute our samples and knowledge to help advance development of the Companys COVID-19 disease severity test.

References:

1. https://www.ohsu.edu/health/ohsu-health-care-awards-and-recognition 2. https://news.ohsu.edu/2020/10/19/preparing-for-the-novel-coronavirus-at-ohsu 3. https://news.ohsu.edu/2020/04/16/ohsu-expedites-promising-new-technologies-to-tackle-covid-19 4. https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P142_avelumab.pdf

- ENDS -

NOTES TO EDITORS:

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of 3D genomic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programs, enabling the personalization of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit our website, http://www.oxfordbiodynamics.com, or follow us on Twitter or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005110/en/

View post:
Oxford BioDynamics Advances EpiSwitch Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University...

Read More...

Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors – BioSpace

October 29th, 2020 10:57 pm

IRVING, Texas, Oct. 27, 2020 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that it has raised $310 million in growth capital.

The financing includes $235 million in equity financing co-led by Highland Capital Management and Coatue, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors.

The Company also raised $75 million in debt from Sixth Street as an extension to the $150 million in structured debt financing Sixth Street invested in September 2018. Sixth Street also participated in the equity round. Following the conclusion of this financing, Vijay Mohan, Co-founding Partner at Sixth Street, has been appointed to the board of directors.

Caris will dedicate the new capital to fund its continued growth in precision medicine to reinvent cancer care, accelerate innovative product development and pursue new initiatives in both the clinical trial and biopharmaceutical markets.

"Caris puts the patient at the center of everything we do, and focuses on fulfilling the promise of improving patient outcomes across all cancer types worldwide. As tumor profiling becomes standard practice, it's important that we continue to grow rapidly as we maintain our leadership position," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "We continue to advance our market-leading tumor profiling platform, clinical trial delivery service, grow our clinical and R&D laboratory facilities, expand our biopharmaceutical partnerships and further expand our investments in AI-powered innovation with our Precision Oncology Alliance collaborators. We are thrilled that our new partners share our vision to be the industry-leader in the precision medicine space."

"This financing represents the first significant external equity investment in Caris. We are tremendously proud to partner with a diverse and high-quality syndicate of leading investors with deep domain knowledge in healthcare and technology," said Brian J. Brille, Vice Chairman of Caris Life Sciences.

"We've reached an inflection point in the ability to use precision medicine to guide treatment decisions for cancer patients. Caris has built the leading clinically-focused comprehensive tumor profiling platform, providing the broadest coverage of actionable biomarkers, unparalleled physician support, and proprietary molecular signature analytics that will continue to enhance the utility of its testing platform for clinicians," said Nate Burns, Portfolio Manager and Head of Healthcare at Highland Capital Management. "The Company is also leveraging its unique multi-omics capabilities and extensive patient outcomes database to pursue compelling new pipeline opportunities including high-sensitivity liquid biopsy diagnostics and novel drug-target identification partnerships. We look forward to working with Caris and are excited about the tremendous growth opportunity ahead."

"By growing its platform, increasing its research and testing capacity, and strengthening its client partnerships, Caris has steadily advanced its position as the leading tumor profiling company," said Vijay Mohan, Co-founding Partner at Sixth Street. "We are proud to continue to support Mr. Halbert, Mr. Brille and the entire Caris team on their mission to help physicians and cancer patients make more personalized and precise treatment decisions. We look forward to our board engagement as Caris keeps leading as an innovator in precision medicine."

About Caris Life SciencesCaris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome whole exome sequencing with 22,000 DNA genes, and MI Transcriptome whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market.

Caris is also advancing precision medicine with Caris MAI (Molecular Artificial Intelligence) that combines its innovative service offerings, Caris Molecular Intelligence with its proprietary artificial intelligence analytics engine, DEAN, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.

Caris Pharmatech is changing the paradigm and streamlines the clinical trial process by assisting biopharma companies with accessing research-ready oncology sites for clinical trials. With over 200 research sites within the Caris Pharmatech Just-In-Time (JIT) Oncology Network, biopharma companies can identify and enroll more patients, faster. Caris Pharmatech Just-In-Time Clinical Trial Solutions focus on rapid site activation and patient enrollment to streamline the drug development process. By implementing Caris' Just-In-Time Trial-Matching System, Caris will automatically match patients to clinical trials and sites can be activated and eligible to enroll patients within one week.

Headquartered in Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit http://www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).

About Highland Capital ManagementHighland Capital Management ("Highland") is a multibillion-dollar global alternative investment platform. Established in 1993 with a focus on the leveraged loan market, Highland has evolved over its more than 25-year history, building on its credit expertise and value-based approach to expand into other asset classes. Today, in addition to high-yield credit, Highland's investment capabilities include real estate, private equity and special situations, public equities, structured credit, and sector- and region-specific verticals built around specialized teams. The platform serves both institutional and retail investors worldwide, offering access to alternatives in a range of investment vehicles and fund structures. Highland operates globally, with offices in Dallas, Texas (headquarters), Buenos Aires, Rio de Janeiro, Singapore, and Seoul. For more information visit http://www.highlandcapital.com.

About CoatueCoatue is one of the largest technology investment platforms in the world with approximately $20 billion in assets under management. Our dedicated team of engineers and data scientists work closely with investment professionals to add value to founders and executive teams in our portfolio. With venture, growth and public funds, we back entrepreneurs from around the globe and at every stage of growth. Some of our private investments have included Airtable, Ant Financial, Anaplan, ByteDance, Chime, Databricks, DoorDash, Instacart, Meituan, Snap and Spotify.

About Sixth StreetSixth Street is a global investment firm with approximately $47 billion in assets under management and committed capital. Sixth Street operates eight diversified, collaborative investment platforms across our growth investing, adjacencies, direct lending, fundamental public strategies, infrastructure, special situations, agriculture and par liquid credit businesses. Our long-term oriented, highly flexible capital base and "One Team" cultural philosophy allow us to invest thematically across sectors, geographies and asset classes. Founded in 2009, Sixth Street has more than 275 team members including over 140 investment professionals operating from nine locations around the world. For more information, visit http://www.sixthstreet.com.

Media and Investor Relations Contact:Argot Partnerscaris@argotpartners.com212-600-1902

Corporate Development Contact:Narendra ChokshiCaris Life Sciencesnchokshi@carisls.com917-689-3511

General Media Contact:Lindsey BailysGCI Healthlindsey.bailys@gcihealth.com212-798-9884

View original content to download multimedia:http://www.prnewswire.com/news-releases/caris-life-sciences-raises-310-million-in-growth-capital-from-a-broad-syndicate-of-leading-investors-301160234.html

SOURCE Caris Life Sciences

Read more here:
Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors - BioSpace

Read More...

TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology…

October 29th, 2020 10:57 pm

DENVER--(BUSINESS WIRE)--Translational Drug Development (TD2), a precision oncology contract research organization (CRO), and VieCure have announced a strategic partnership that will provide patients receiving care in community oncology practices with best-in-class precision oncology treatments while enhancing patient awareness of tailored treatment and clinical studies that are most likely to benefit them.

A paradigm shift has occurred in favor of precision oncology, in which the molecular profile of a patients tumor is guiding treatment related decision-making. There has been an unprecedented increase in the number of approved novel immunotherapy and targeted agents across different indications over the past five years. The combination of TD2 and VieCure will allow a greater number of oncologists to embrace the latest clinical guidance, increase access to trials, have ease of access to next generation tumor sequencing, and facilitate enhanced access to the right care, for the right patient, at the right time.

We believe community oncology practices are critical to the success for new oncology medicines and this partnership increases the likelihood of clinical benefit for patients and overall success of clinical trials," said Stephen Gately, President and CEO at TD2. VieCures platform puts critical patient data like genomics, and proteomics at oncologists fingertips as they meet with their patients so that they are immediately aware of potential precision oncology trials that their patient is eligible for.

Access to de-identified real-time patient data will enhance TD2s ability to identify the right patients with much greater fidelity and speed, ultimately resulting in better outcomes for cancer patients.

The VieCure Platform is the ideal vehicle to help drive precision oncology adoption in community-based practice, said Dr. Fred Ashbury, Chief Scientific Officer at VieCure, Our Artificial Intelligence engine supports clinicians by presenting options that may have otherwise gone unnoticed, further emphasizing the need for clinical decision support tools at the point of care to help manage the precision oncology revolution.

Participating community oncology practices will have access to industry-sponsored clinical trials codified into the VieCure platform. This will improve trial design and speed up the opening of precision oncology clinical trials and the real time collection of data in the community oncology setting. This relationship will result in a greater number of patients having access to new and novel therapies.

About TD2

TD2, based in Scottsdale, Arizona, focuses on oncology medicine development with unparalleled experience conducting translational studies from bench-to-bedside against all tumor times and hematology indications. TD2 provides end-to-end solutions, including translational preclinical services; regulatory strategic guidance, planning and document submission service; and clinical trail design and execution for innovative oncology-focused companies. TD2 has provided its services to more than 600 biotech and pharma companies, maintaining hundreds of studies per year. Among them, the team has been involved in more than 600 first-in-man major oncology medicines, including numerous trials that have led to approvals in both rare and large indications.

About VieCure

VieCure has developed a proprietary artificial intelligence informatics software platform in conjunction with a clinical inference engine and smart electronic medical record in oncology. The VieCure platform is a real-time decision support system that combines clinical knowledge with patient data to assist oncologists and hematologists in generating personalized treatment plans and managing a patients treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. For more information, please visit http://www.viecure.com and connect with VieCure on LinkedIn, Facebook and Twitter.

Visit link:
TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology...

Read More...

Global Healthcare Biomarkers Market 2020 COVID-19 Updated Analysis By Product (Safety biomarker, Validation biomarker, Efficacy biomarker); By…

October 29th, 2020 10:57 pm

Global Healthcare Biomarkers Market Report Covers Market Dynamics, Market Value Chain, And Future Prospective

Healthcare Biomarkers marketis experiencing a growth that the global industry has never-ever seen before. The considerable growth and development are basically due to the current increasing demand and supply on the global platform. The current market dossier provides the necessary details such as the monetary fluctuations, industrial trade, future scopes, and global market status in a smooth-tongued pattern.

The Healthcare Biomarkers market report has some of the major players Johnson & Johnson, Qiagen N.V., GE Healthcare, Agilent Technologies, Roche Diagnostics, Merck, Thermo Fisher Scientific, Bio-Rad Laboratories, Abbott Laboratories, Epigenomics AG, Siemens Healthcare GmbH leading the current global market mentioned. The research report has all the vital details about the past, present, and future aspects of the Healthcare Biomarkers market mentioned with great transparency.

Click here for the free sample copy of the Healthcare Biomarkers Market report

An Overview About the Table of Contents:

Global Healthcare Biomarkers Market Overview Target Audience for the Healthcare Biomarkers Market Economic Impact on the Healthcare Biomarkers Market Global Healthcare Biomarkers Market Forecast Business Competition by Manufacturers Production, Revenue (Value) by Region Production, Revenue (Value), Price Trend by Type Market Analysis by Application Cost Analysis Industrial Chain, Sourcing Strategy, and Downstream Buyers Marketing Strategy Analysis, Distributors/Traders Market Effect Factors Analysis

In the global market, there is always a tough competition going on between the various players so as to top the chart. The current Healthcare Biomarkers market seems to have succeeded in sowing its seed of success and is enjoying the benefits of the reaping taking place on a global platform. The most important aspect provided in the report is the variation in the financial scale that can give the clients a complete idea about the current monetary gain and loss. The geographical segmentation North America (United States, Canada and Mexico), Europe (Germany, UK, France, Italy, Russia and Turkey etc.), Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam), South America (Brazil, Argentina, Columbia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) gives the readers an entire data about the growth and development taking place across the world. The informative report also presents some data based on the market bifurcations, growth factors, futuristic aspects, industrial policies, and product supply and demand for a better piece of understanding.

Read Detailed Index of full Research Study at::https://www.marketdataanalytics.biz/global-healthcare-biomarkers-market-report-2020-by-key-players-72994.html

Key Insights encompassed in the Healthcare Biomarkers market report

Latest technological advancement in the Healthcare Biomarkers market Studying pricing analysis and market strategies trailed by the market players to enhance global Healthcare Biomarkers market growth Regional development status off the Healthcare Biomarkers market and the impact of COVID-19 in different regions Detailing of the supply-demand chain, market valuation, drivers, and more

One of the vital data mentioned in the report includes that of the overall market segmentation based on the product type, applications, end-users, and various other subtypes. The market segmentation {Safety biomarker, Validation biomarker, Efficacy biomarker}; {Diagnostics development, Personalized medicine, Drug discovery & development, Disease risk assessment, Other} helps the clients and other readers obtain a crystal-clear context about the Healthcare Biomarkers market. The knowledgeable aspects mentioned in the current scientific report is made available at the tip of the finger with just a click.

Questions answered by the Healthcare Biomarkers market report:

Which are regions witnessing the highest growth during the forecast period? How the surging prices of raw materials will affect the growth of the Healthcare Biomarkers market? Which are major market players? How are the market players intensifying their global presence? If yes, how? What are the key strategies used by the market players to improve their market position post the COVID-19 pandemic?

Enquire Here Get customization & check discount for report@https://www.marketdataanalytics.biz/global-healthcare-biomarkers-market-report-2020-by-key-players-72994.html#inquiry-for-buying

Why Choose Market Data Analytics reports?

Our analysts use latest market research techniques to create the report Market reports are curated using the latest market research and analytical tools Customization of report is possible as per the requirement Our team comprises of expertise and highly trained analysts Quick responsive customer support for domestic and international clients

Read more:
Global Healthcare Biomarkers Market 2020 COVID-19 Updated Analysis By Product (Safety biomarker, Validation biomarker, Efficacy biomarker); By...

Read More...

The Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR from 2020 to 2025 – PRNewswire

October 29th, 2020 10:57 pm

NEW YORK, Oct. 29, 2020 /PRNewswire/ -- The research antibodies and reagents market is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period. The research antibodies and reagents market has evolved owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research reproducibility, and increasing R&D activity and expenditure in the life sciences industry. Fueled by the growing demand for personalized medicine and structure-based drug design, the global research antibodies and reagents market is expected to witness significant growth in the coming years.

Read the full report: https://www.reportlinker.com/p05979661/?utm_source=PRN

Based on product, the reagents segment holds the highest market share during the forecast period.Based on product, the research antibodies and reagents market are segmented into reagent and antibodies.The reagent segment accounted for the larger market share in 2019.

The reagents market is experiencing notable growth due to the growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields.

Based on technology, the flow cytometry segment is expected to register the highest CAGR during the forecast period.Based technology, the research antibodies and reagents market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies.The flow cytometry segment is expected to witness the highest growth during the forecast period.

This is mainly due to this technique is its ability to perform simultaneous multi-parameter analysis on single cells within a heterogeneous mixture.It offers high throughput and the automated quantification of cell features.

These factors, along with technological innovations in flow cytometry and growing cancer research, are driving the growth of this segment. By application , the proteomics holds the highest market share during the forecast period.

Based on application, the research antibodies and reagents market is segmented into proteomics, drug development and Genomics. Proteomics held the largest share of the global research antibodies and reagents market in 2019.The growth of the segment is due to as it efficiently maps drug-protein and protein-protein interactions. Moreover, proteomic technologies have minimized the cost, time, and resource requirements for chemical synthesis and biological testing of drugs. Proteomic technologies, such as electrophoresis, ELISA, microarrays, and MS-based proteomics, are highly efficient for analytical laboratory testing.

By enduser , the pharmaceutical & biotechnology holds the highest market share during the forecast period.The research antibodies and reagents market is segmented into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations.The pharmaceutical & biotechnology companies held the largest share of the global research antibodies and reagents end-user market in 2019.

The large share of this segment is attributed to the wide use of research antibodies in drug development for the identification and quantification of biomarkers and various analytical procedures. By Region, The Asia Pacific region is expected to register the highest CAGR during the forecast period.

The Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR from 2020 to 2025.The growth of this market is primarily due to growing proteomics and genomics research and increasing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics in the region. Also high-growth countries, such as China, India, Japan, South Korea, Taiwan, Australia, and Singapore are the major contributors to the Asia Pacific research antibodies and reagents market. This region is expected to grow at the highest pace during the forecast period primarily due to growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics.

Break of primary participants was as mentioned below: By Company Type Tier 135%, Tier 245% and Tier 320% By Designation C-level35%, Director-level25%, Others40% By Region North America45%, Europe30%, Asia Pacific20%, Latin America- 3%, Middle East and Africa2%

Key players in the research antibodies and reagents marketThe key players operating in the researsch antibodies and reagents systems include Thermo Fisher Scientific (US), Merck Group (Germany), Abcam plc (UK), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US).

Research Coverage:The report analyzes the research antibodies and reagent market and aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, and region.The report also includes a product portfolio matrix of various research antibodies and reagents products available in the market.

The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the ReportThe report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers: Market Penetration: Comprehensive information on product portfolios offered by the top players in the global research antibodies and reagent market. The report analyzes this market by product and distribution channel. Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global research antibodies and reagent market. Market Development: Comprehensive information on the lucrative emerging markets by product and distribution channel Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global research antibodies and reagent market. Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global research antibodies and reagent market.

Read the full report: https://www.reportlinker.com/p05979661/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read this article:
The Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR from 2020 to 2025 - PRNewswire

Read More...

Medidata NEXT Global 2020 to Focus on the Virtualization of Clinical Trials, the Power of Analytics and Improving the Patient Experience in the…

October 29th, 2020 10:57 pm

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systmes company, the global leader in creating end-to-end solutions that support the entire clinical trial process, will convene stakeholders in drug and device development, clinical operations, data management, biostatistics and digital medicine innovation industries for NEXT Global on October 27-29, 2020.

With a focus on improving clinical trials through advanced technology and enhancing the patient experience, the three-day, all virtual event will bring together experts to discuss topics critical to pharmaceutical and biotechnology companies, medical device and diagnostics companies, and contract research organizations (CROs) running clinical trials during the COVID-19 pandemic.

The COVID-19 pandemic is reshaping the life sciences industry and is acting as a catalyst for dramatic change, said Tarek Sherif, co-founder and co-CEO of Medidata. Digital transformation of life sciences is happening at an accelerated pace, from research to clinical trials, manufacturing and through to commercialization. Nowhere is this more apparent than in clinical studies, where the use of advanced analytics is powering faster, safer and more effective treatments. Medidatas platform is at the forefront of enabling clinical development to improve the patient experience and patient outcomes.

To see and hear how Medidatas industry-leading Rave platform and its innovative patient-centric approach is at the core of digitally transforming clinical trials, attendees will participate in sessions with the following themes:

Presentations from Medidata experts, customers, partners and industry experts will focus on the next phase of digital transformation in clinical trials and drug development through:

The right unified technology can embrace the waves of change and increase precision in medical therapies and treatments, said Glen de Vries, co-CEO of Medidata. NEXT Global will showcase technology solutions that accelerate clinical development, powering smarter treatments and healthier people.

Medidata is a wholly owned subsidiary of Dassault Systmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,600+ customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at http://www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.

Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systmes.

About Dassault Systmes

Dassault Systmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systmes brings value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit http://www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systmes, a French socit europenne (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Read more here:
Medidata NEXT Global 2020 to Focus on the Virtualization of Clinical Trials, the Power of Analytics and Improving the Patient Experience in the...

Read More...

Fabric Genomics to Co-market Comprehensive Sample-to-Genomic Analysis Sequencing Solutions for Hereditary Genetics – BioSpace

October 29th, 2020 10:57 pm

Oct. 26, 2020 16:00 UTC

OAKLAND, Calif.--(BUSINESS WIRE)-- In a step toward the full realization of genomic medicine, Fabric Genomics (Formerly Known As Omicia, Inc.), a leader in AI-based genomic analysis and interpretation, has announced a co-marketing agreement that will provide translational researchers around the world with integrated sample prep to reporting workflows. Combining Roches newly released KAPA HyperExome Probes (RUO) with the Fabric Enterprise bioinformatics and analysis platform will make genetic research faster, less costly and more accurate by providing an end-to-end solution from sample prep through analysis.

Fabric Genomics pioneered AI-driven genomic interpretation, and its Fabric Enterprise software platform for genomic data analysis and reporting is in use by clinical research laboratories, healthcare institutions and country sequencing programs around the world, including Rady Childrens Institute for Genomic Medicine, LabCorp and Genomics England. Last week Fabric Genomics released Fabric GEM, a novel algorithm that quickly identifies the likely genetic cause of rare diseases; the new technology is fully integrated within the Fabric Enterprise platform.

Roches exome sequencing workflow includes the KAPA HyperPrep and HyperPlus library preparation kits and exome probes, which allow users to quickly prepare samples for sequencing while delivering high on-target rates and 98% sensitivity for SNP detection.

In addition to improving turnaround times for genomic sequencing, the combination of these technologies will allow laboratories to increase automation and lower operational costs with improved scalability. Clinical research labs that are expanding assay menus will benefit from reduced costs of development and faster validation.

Clinical research labs have a need to take a collected sample from library prep quickly, all the way through to analysis, and our agreement with Roche demonstrates our commitment to supporting these critical workflows, said Martin Reese, PhD, co-founder and CEO of Fabric Genomics. Using our Fabric Enterprise analysis platform with Roche KAPA HyperExome Probes ensures high coverage of disease-causing genes, which is of the utmost importance in accelerating the identification of rare variants. Combining these technologies into a single workflow will lead to higher quality results and increased reliability of sequencing-based diagnostics in routine care. With widespread adoption of sequencing technology innovation, we can further our shared goal of improving personalized care.

KAPA products are for research use only (RUO). Not for use in diagnostic procedures.

About Fabric Genomics

Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics. Fabric Genomics is making genomics-driven precision medicine a reality. The company also provides clinical decision-support software that enables clinical labs, hospital systems and country sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabrics end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology.

To learn more, visit https://fabricgenomics.com/roche/ and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005324/en/

See original here:
Fabric Genomics to Co-market Comprehensive Sample-to-Genomic Analysis Sequencing Solutions for Hereditary Genetics - BioSpace

Read More...

This Mid-Cap Stock Fund Wins With Warren Buffetts Strategy – Barron’s

October 29th, 2020 10:57 pm

Mid-cap stocks are oftenunfairlyoverlooked. In a coronavirus-stricken economy where giant tech companies keep powering the market higher as small companies struggle to survive, mid-caps are an excellent compromise. They generally have lower valuations than the most beloved blue chips and stronger businesses than the small fries.

In fund tracker Morningstars Mid-Cap Blend category, the $552 million Madison Mid Cap fund (ticker: GTSGX) is one of the best. The no-load fund has beaten 95% of its category peers in the past three years and 85% of them in the past 15. Equally important, it is less volatile than its Russell Midcap benchmark, while matching the indexs 11.8% average annual return in the past 10 years. (Although officially this Y-share class of the fund has a $25,000 minimum investment, brokers such as Fidelity, Charles Schwab, TD Ameritrade, and E*Trade allow clients to get into the fund with an investment of $2,500 or less.)It has an expense ratio of 0.95%.

Manager Rich Eisinger, 55, has been at the helm since 1998, but he also relies on Haruki Toyama, co-manager since 2015, and Andy Romanowich, co-manager since 2019. Eisingers connection with Toyama, 49, goes way back. They first met at an investment club in the 1990s at Cornell Universitys business school, and both were Warren Buffett fans. We showed up at a room for new club members, and this fellow student got up, and started talking about options this and options that, and Rich and I kind of looked at each other and were like, Whats this guy talking about? We just want to buy great companies at a cheap price, Toyama recalls. They have been friends since then, swapping investment ideas, going on research trips together, and sharing investment philosophies.

Eisingers investment style, like Buffetts, has evolved from a more traditional value approachseeking cheap stocksto trying to invest in great businesses with strong durable cash flows. Over time, weve realized, especially in the mid-cap space, the value of paying up for a great business and watching that free cash flow compound over many years, Eisinger says. Madison Mid Cap tends to hold stocks for the long termthe funds turnover ratio is 25%, indicating a typical holding period of four years. Forty percent of our portfolio weve owned for over a decade, Toyama says.

The fund is also concentratedanother Buffett hallmarkhaving just 29 stocks as of Sept. 30. Concentration increases individual stock risk, as any blowups in a 5% position hurt returns more than a 1% one, for instance. But the funds volatility is low, despite its small number of stocks, reflecting the high quality of its holdings and the rarity of individual company blowups.

To make it into the portfolio, a company should have a strong business model with an economic moat that prevents competitors from reducing profits. It must also have a superior management team with preferably strong insider ownership, conservative accounting and earnings projections, and a history of wise capital-allocation decisions regarding share buybacks, acquisitions, and debt repayment. Finally, the valuation must be reasonable for a strong business.

Note: Holdings as of Sept. 30. Returns through Oct. 26; all returns are annualized.

Sources: Madison Funds; Morningstar

Health-care diagnostics company Laboratory Corp. of America Holdings (LH), commonly known as LabCorp, exemplifies the funds buy-and-hold strategy. Were in the 17th year now of ownership, Eisinger says. LabCorp and Quest Diagnostics (DGX) are the two largest clinical diagnostics labs in the country, controlling 25% of the independent lab business, he says. Eisinger sees a long runway for earnings growth between 10% to 11% a year because LabCorp is the low-cost provider of diagnostic tests relative to hospital labs. Theres more emphasis on [health-care] cost containment than theres ever been, so [LabCorp] is going to start gaining more market share in the next decade.

Moreover, in 2015 LabCorp acquired drug developer Covance, which specializes in personalized medicine, such as targeted gene therapies. Covance can utilize LabCorps huge database of patients to get candidates for their drug trials and their drug development, Eisinger says. That patient access should give Covance an advantage in the burgeoning personalized medicine business.

Another favorite, property and casualty insurer Arch Capital Group (ACGL), has a CEO, Marc Grandisson, who embodies the Buffett-like qualities that the fund managers seek. In fact, in the 1990s, Grandisson actually worked at Berkshire Hathaway (as did his predecessor, Constantine Iordanou, who is now retired). Under Grandissons aegis, Arch has been an excellent capital allocator and one of the few insurers to make a profit from its policy underwriting, Toyama says. Historically, the industry has lost money underwriting, and made it up in investments, he says, referring to how insurers typically use money from policy premiums to buy bonds and stocks.

Archs insurance underwriting has been successful because Grandisson is willing to walk away from business when a policy type becomes less profitable or commodity-like due to competition, Toyama says. It has decreased its major casualty insurance business over the years as it got more price competitive, he explained. The companys stock has taken a shellacking in 2020, down 29%, because of claims related to Covid-19. But it is precisely after such calamities that insurance premiums go up and profitability increases, Toyama says. The fund is staying put.

Typical of a high-quality mid-cap portfolio, many of the funds holdings are industry leaders but not household names. So 16% of its portfolio is in technology, but not in the Amazon.coms (AMZN) of the world. Instead, the fund invests in companies like tech research publisher and consultant Gartner (IT).

Newsletter Sign-up

Every weekday evening we highlight the consequential market news of the day and explain what's likely to matter tomorrow.

Gartner has a very attractive business model in that its core product is a written research service that is sold on a subscription basis, Romanowich says. So, it has very visible, highly recurring revenue. The company has a major advantage as the leading research intermediary between tech buyers and sellers, he says. Gartner knows what end users want, and what corporations tech road maps look like. They also know what tech vendors are thinking and what their technology road maps look like.

That informational advantage provides an economic moat any Warren Buffett fan would admire.

Write to editors@barrons.com

Read more from the original source:
This Mid-Cap Stock Fund Wins With Warren Buffetts Strategy - Barron's

Read More...

Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 – The Think Curiouser

October 29th, 2020 10:56 pm

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1889<ype=S

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Originally posted here:
Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 - The Think Curiouser

Read More...

Page 349«..1020..348349350351..360370..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick